Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Akanda Corp (AKAN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: AKAN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.14% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.30M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.5 | 52 Weeks Range 0.93 - 5.08 | Updated Date 06/29/2025 |
52 Weeks Range 0.93 - 5.08 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -564.33% |
Management Effectiveness
Return on Assets (TTM) -32.7% | Return on Equity (TTM) -1460.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -185776 | Price to Sales(TTM) 3.94 |
Enterprise Value -185776 | Price to Sales(TTM) 3.94 | ||
Enterprise Value to Revenue 3.2 | Enterprise Value to EBITDA -0.8 | Shares Outstanding 2275900 | Shares Floating 2257628 |
Shares Outstanding 2275900 | Shares Floating 2257628 | ||
Percent Insiders 0.8 | Percent Institutions 0.51 |
Upturn AI SWOT
Akanda Corp
Company Overview
History and Background
Akanda Corp was a cannabis company focused on the medical cannabis market. It aimed to provide pharmaceutical-grade cannabis products to patients in Europe and Africa. The company aimed to be a leader in cannabis cultivation, manufacturing, and distribution. The company ceased operations and filed for bankruptcy in 2023.
Core Business Areas
- Cultivation: Akanda focused on cultivating high-quality medical cannabis. This involved growing cannabis plants in controlled environments to ensure consistency and potency.
- Manufacturing: The company processed raw cannabis into various pharmaceutical-grade products. This included extracting cannabinoids and formulating them into different dosage forms.
- Distribution: Akanda aimed to distribute its products through established pharmaceutical channels to reach patients in Europe and Africa. This involved securing regulatory approvals and partnerships with distributors.
Leadership and Structure
The company had a CEO and a management team responsible for overseeing the various aspects of the business, from cultivation and manufacturing to distribution and sales. Details of specific individuals are difficult to obtain since the company ceased operations.
Top Products and Market Share
Key Offerings
- Medical Cannabis Flower: Dried cannabis flower for vaporization or smoking. Market share data is unavailable due to the company's closure. Competitors included Aurora Cannabis (ACB), Canopy Growth Corporation (CGC), and Tilray (TLRY).
- Cannabis Oils: Cannabis extracts formulated into oils for oral consumption or topical application. Market share data is unavailable. Competitors included Aurora Cannabis (ACB), Canopy Growth Corporation (CGC), and Tilray (TLRY).
- Other Cannabis Products: Varied products for pain relief such as cannabis gummies and capsules. Market share data is unavailable. Competitors included Aurora Cannabis (ACB), Canopy Growth Corporation (CGC), and Tilray (TLRY).
Market Dynamics
Industry Overview
The medical cannabis industry is a rapidly growing market driven by increasing legalization and acceptance of cannabis for medical purposes. The market is competitive and heavily regulated.
Positioning
Akanda aimed to position itself as a leading supplier of high-quality medical cannabis products in Europe and Africa. The company's competitive advantage was supposed to be its focus on pharmaceutical-grade products and its international expansion strategy.
Total Addressable Market (TAM)
The TAM for medical cannabis globally is estimated to be in the tens of billions of dollars annually. Akanda aimed to capture a significant share of this market by focusing on key regions in Europe and Africa, but failed to execute and capture value.
Upturn SWOT Analysis
Strengths
- Focus on Pharmaceutical-Grade Products
- International Expansion Strategy (Europe & Africa)
- Potential for Strong Brand Recognition
Weaknesses
- Limited Operating History
- High Capital Requirements
- Dependence on Regulatory Approvals
- Failed to execute business objectives
- Went bankrupt in 2023
Opportunities
- Expanding Medical Cannabis Market
- Increasing Acceptance of Cannabis for Medical Purposes
- Potential for Partnerships with Pharmaceutical Companies
Threats
- Intense Competition
- Stringent Regulations
- Fluctuations in Cannabis Prices
- Changing Consumer Preferences
- Significant debt load
Competitors and Market Share
Key Competitors
- ACB
- CGC
- TLRY
Competitive Landscape
Akanda Corp faced intense competition from established players in the medical cannabis market. The company's lack of financial resources and operational challenges hindered its ability to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: The company experienced limited growth and struggled to achieve profitability.
Future Projections: Future projections are irrelevant due to the company's bankruptcy.
Recent Initiatives: Recent initiatives failed to improve the company's financial performance.
Summary
Akanda Corp was a cannabis company that aimed to be a leader in the medical cannabis market in Europe and Africa. However, the company failed to execute its business plan and filed for bankruptcy. Its focus on pharmaceutical-grade products and international expansion strategy were promising, but it struggled with competition, regulations, and financial challenges. The company's stock is now worthless, and investors have lost their investments. It is an example of the challenges of navigating the cannabis market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Public filings
- Market analysis reports
- Company press releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. The company is bankrupt, and the stock is worthless. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akanda Corp
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2022-03-15 | Interim CEO & Executive Director Ms. Katharyn Field | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website https://www.akandacorp.com |
Full time employees - | Website https://www.akandacorp.com | ||
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products. The company was incorporated in 2021 and is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.